Lineage Cell Therapeutics, Inc.
LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyteā¦ read more
Healthcare
Biotechnology
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.08
Price-2.70%
-$0.03
1Y
Price
Market Cap
$269.242m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-803.4%
EBITDA Margin-809.0%
Net Profit Margin-98.6%
Free Cash Flow Margin-803.4%
EBITDA Margin-809.0%
Net Profit Margin-98.6%
Free Cash Flow MarginRevenue
$14.779m
+13.9%
1y CAGR-6.4%
3y CAGR+64.6%
5y CAGREarnings
-$64.206m
-263.6%
1y CAGR-77.3%
3y CAGR-48.3%
5y CAGREPS
-$0.28
-222.2%
1y CAGR-59.1%
3y CAGR-33.7%
5y CAGRBook Value
$52.695m
$109.533m
Assets$56.838m
Liabilities$2.394m
DebtDebt to Assets
2.2%
-0.1x
Debt to EBITDAFree Cash Flow
-$22.303m
+11.8%
1y CAGR-1531.8%
3y CAGR-1123.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company